A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine Produced by IVAC in Adults Aged 18-60 Years in Vietnam
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Solicited Adverse Events
Study Overview
Brief Summary
This prospective, single-center, randomized, placebo-controlled, observer-blind Phase 1/2 study includes two separate parts.
Part 1 is a first-in-human, Phase 1 study designed to evaluate the safety, tolerability and immunogenicity of the COVIVAC vaccine at three different dose levels (1, 3, and 10 µg) without adjuvant, and at one dose level (1 µg) with the adjuvant CpG 1018, in a total of 120 subjects aged 18-59 years. (Part 2 will be registered in a separate record)
Detailed Description
This prospective, single-center, randomized, placebo-controlled, observer-blind Phase 1/2 study includes two separate parts.
Part 1 is a first-in-human, Phase 1 study designed to evaluate the safety, tolerability and immunogenicity of the COVIVAC vaccine at three different dose levels (1, 3, and 10 µg) without adjuvant, and at one dose level (1 µg) with the adjuvant CpG 1018, in a total of 120 subjects aged 18-59 years.
An interim analysis of Phase 1 data conducted after the last subject last visit for V6 (D57) will serve as the basis for decisions about down selection and advancing to Part 2 of the study (Phase 2). Down selection and advancement to Part 2 (Phase 2) will be based on the following parameters:
- Post-dose 2 immunogenicity results at the aggregate treatment level
o A threshold immune response at Visit 5 (D43) will be required: the observed seroresponse rate in a treatment group (defined as the percentage of subjects with at least a 4-fold rise from baseline in 80% neutralizing antibody titers) will need to be ≥52% at the LL of the 95% CI for that treatment (vaccine formulation) to be considered for advancement to Phase 2.
- Post-dose 1 and post dose 2 safety results including all solicited and unsolicited adverse events, serious adverse events, and clinical laboratory results.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Phase 1 Only:
- •Adult 18 through 59 years of age inclusive at the time of randomization.
- •Healthy, as defined by absence of clinically significant medical condition, either acute or chronic, as determined by medical history, physical examination, screening laboratory test results, and clinical assessment of the investigator.
- •Has provided written informed consent prior to performance of any study-specific procedure.
- •Has a body mass index (BMI) of 17 to 40 kg/m2, inclusive, at screening.
- •Resides in study site area and is able and willing to adhere to all protocol visits and procedures.
- •If a woman is of childbearing potential, must not be breastfeeding or be pregnant (based on a negative urine pregnancy test at screening and during the 24 hours prior to receipt of the first dose of IP), must plan to avoid pregnancy for at least 28 days after the last dose of IP, and be willing to use an adequate method of contraception consistently and have a repeated pregnancy test prior to the second (last) dose of IP.
Exclusion Criteria
- •Use of any investigational medicinal product within 90 days prior to randomization or planned use of such a product during the period of study participation.
- •History of administration of any non-study vaccine within 28 days prior to administration of study vaccine or planned vaccination within 3 months after enrolment.
- •Note: receipt of any COVID-19 vaccine that is licensed or granted Emergency Use Authorization in Vietnam during the course of study participation is not exclusionary if administered after Visit
- •Previous receipt of investigational vaccine for SARS or MERS, or any investigational or licensed vaccine that may have an impact on interpretation of the trial results
- •History of hypersensitivity reaction to any prior vaccination or known hypersensitivity to any component of the study vaccine
- •History of egg or chicken allergy
- •History of angioedema
- •History of anaphylaxis
- •Acute illness (moderate or severe) and/or fever (body temperature measured orally ≥38°C)
- •Any abnormal vital sign deemed clinically relevant by the PI
- •Abnormality in screening laboratory test deemed exclusionary by the PI in consultation with the Sponsor
- •A positive serologic test for hepatitis B (HBsAg) or hepatitis C (HCV Ab)
- •History of confirmed HIV
- •History of laboratory-confirmed COVID-19
- •History of malignancy, excluding non-melanoma skin and cervical carcinoma in situ
- •Any confirmed or suspected immunosuppressive or immunodeficient state
- •Administration of immunoglobulin or any blood product within 90 days prior to first study injection or planned administration during the study period.
- •Administration of any long-acting immune-modifying drugs (e.g., infliximab or rituximab) or the chronic administration (defined as more than 14 days) of immunosuppressants within six months prior to first study injection, or planned administration during the study period (includes systemic corticosteroids at doses equivalent to ≥ 0.5 mg/kg/day of prednisone; the use of topical steroids including inhaled and intranasal steroids is permitted).
- •History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding. (e.g, thalassemia, coagulation factor deficiencies).
- •Recent history (within the past year) or signs of alcohol or substance abuse.
- •Any medical, psychiatric or behavior condition that in the opinion of the PI may interfere with the study objectives, pose a risk to the subject, or prevent the subject from completing the study follow-up.
- •Employee of any person employed by the Sponsor, the contract research organization (CRO), the PI, study site personnel, or site.
Arms & Interventions
COVIVAC 1mcg
1mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
Intervention: COVIVAC (Biological)
COVIVAC 3mcg
3mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
Intervention: COVIVAC (Biological)
COVIVAC 10mcg
10mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
Intervention: COVIVAC (Biological)
COVIVAC 1mcg + CpG1018 1.5mg
1mcg + CpG1018 IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
Intervention: COVIVAC (Biological)
Placebo
Phosphate buffered saline (pH 7.2) for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
Intervention: Phosphate-buffered saline (Biological)
Outcomes
Primary Outcomes
Solicited Adverse Events
Time Frame: During the first 7 days after each vaccination
Percentage of participants with solicited local and systemic adverse events (AEs)
Clinical Safety Tests
Time Frame: At 7 days post each vaccination
Percentage of participants with clinically significant hematological and biochemical abnormalities
Unsolicited Adverse Events
Time Frame: During the first 28 days after each vaccination
Number of participants with any unsolicited adverse event
Serious Adverse Event
Time Frame: Throughout the Study Period (until Day 197)
Number of participants with serious adverse events (SAEs)
Medical Attended Adverse Events
Time Frame: Throughout the Study Period (until Day 197)
Number of participants with medically-attended AEs (MAAEs)
Adverse Event of Special Interest
Time Frame: Throughout the Study Period (until Day 197)
Number of participants with adverse events of special interest (AESI) , including AESI relevant to COVID-19, and potential immune-mediated medical conditions (PIMMC)
Secondary Outcomes
- GMT of 50% Neutralizing Antibody (NT50)(GMT of NT50 at 28 days after first vaccination, at 14 days and 6 months after the second vaccination)
- Geometric Mean Fold Rise (GMFR)(GMFR at 28 days after first vaccination, at 14 days and 6 months after the second vaccination)
- Seroresponse in NT50(Seroresponse at 28 days after first vaccination, at 14 days and 6 months after the second vaccination)
- Anti-S IgG GMC(GMC of Anti-S IgG at 28 days after the first vaccination, at 14 days and 6 months after the second vaccination)
- GMFR in Anti-S IgG GMC(GMFR at 28 days after the first vaccination, 14 days and 6 months after the second vaccination)
- Seroresponse in Anti-S IgG Concentration(Seroresponse at 28 days after the first vaccination, 14 days and 6 months after the second vaccination)